Login
Business
Entertainment
World
Health
Environment
Lifestyle
National
Science
Sports
World
Movies
Web Series
Technology
Cricket
Coronavirus
Auto
Ajab Ghazab
Finance
India
International
Religious
Politics
Home Articles Biosimilars Companies
Glenmark Pharma reports revenue of Rs 27,773 Mn and PAT of Rs 2,111 Mn for Q1 FY 2022-23 \
6 min read
\
\

Glenmark Pharma reports revenue of Rs 27,773 Mn and PAT of Rs 2,111 Mn for Q1 FY 2022-23

 11-Aug-2022
Mumbai (Maharashtra) [India], August 11 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven global pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2022.
11-Aug-2022 Business
\
Glenmark launches sitagliptin and its fixed-dose combinations, at affordable price for adults with type 2 diabetes in India \
4 min read
\
\

Glenmark launches sitagliptin and its fixed-dose combinations, at affordable price for adults with type 2 diabetes in India

 08-Jul-2022
Mumbai (Maharashtra) [India], July 8 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched sitagliptin and its Fixed Dose Combinations (FDCs), at affordable prices for adults with Type 2 diabetes in India. The company has introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT® and its variants at affordable prices.
08-Jul-2022 Business
\
Glenmark launches ‘Hello Skin’ – India’s first Whatsapp based chatbot to help patients suffering from fungal infections \
5 min read
\
\

Glenmark launches ‘Hello Skin’ – India’s first Whatsapp based chatbot to help patients suffering from fungal infections

 24-May-2022
Mumbai (Maharashtra) [India], May 24 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark), an innovation-led global pharmaceutical company, has developed a digital patient education tool, 'Hello Skin' in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists), to help patients suffering from Dermatophytosis (Ring Worm or Tinea) in India, to adhere to the recommended treatment duration.
24-May-2022 Business
\
Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India \
4 min read
\
\

Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India

 25-Apr-2022
Mumbai (Maharashtra) [India], April 25 (ANI/PR Newswire): Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day.
25-Apr-2022 Business
\